# Xilio Therapeutics to Present at the Leerink Partners Global Healthcare Conference
Canonical URL: https://biopharmsignal.com/news/XLO/xilio-therapeutics-to-present-at-the-leerink-partners-global-healthcare-conferen-8fe4e6c2
Ticker: XLO
Company: Xilio Therapeutics
Source: Xilio Therapeutics
Published: 2026-03-02 13:00 EST
## Summary

Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and...

## Article Body
Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced that company management will participate in a fireside chat during the Leerink Partners Global Healthcare Conference on Monday, March 9, 2026 at 3:00 p.m. ET.

A live webcast can be accessed under “Events & Presentations” in the Investors & Media section of the Xilio Therapeutics website at ir.xiliotx.com . A replay of the webcast will be archived on the website for 30 days following the presentation.

About Xilio Therapeutics

Xilio Therapeutics is a clinical-stage biotechnology company discovering and developing masked immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is leveraging its proprietary masking technology to advance a pipeline of novel, masked I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment. Learn more by visiting www.xiliotx.com and follow us on LinkedIn ( Xilio Therapeutics, Inc. ).

Investor Contact Alex Lobo, Precision AQ alex.lobo@precisionaq.com

Media Contact Josie Butler, 1AB josie@1abmedia.com
## Recent Company News
- 2026-07-06 20:30 EST — [Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/XLO/xilio-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c--f70a7f47) — Source: Xilio Therapeutics
- 2026-06-29 11:30 EST — [Xilio Therapeutics Appoints Ben Harshbarger as Chief Legal Officer](https://biopharmsignal.com/news/XLO/xilio-therapeutics-appoints-ben-harshbarger-as-chief-legal-officer-d248a423) — Source: Xilio Therapeutics
- 2026-05-12 11:30 EST — [Xilio Therapeutics Reports First Quarter 2026 Financial Results and Provides Pipeline and Business Updates](https://biopharmsignal.com/news/XLO/xilio-therapeutics-reports-first-quarter-2026-financial-results-and-provides-pip-859a3b0c) — Source: Xilio Therapeutics
- 2026-05-07 20:30 EST — [Xilio Therapeutics Announces Inducement Grants Under  Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/XLO/xilio-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c--057e4f7c) — Source: Xilio Therapeutics
- 2026-04-17 20:01 EST — [Xilio Therapeutics Announces New Preclinical Data at AACR Annual Meeting for XTX601, a Masked T Cell Engager Targeting CLDN18.2](https://biopharmsignal.com/news/XLO/xilio-therapeutics-announces-new-preclinical-data-at-aacr-annual-meeting-for-xtx-61e9b86b) — Source: Xilio Therapeutics
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)